Cencora is a global pharmaceutical distributor and healthcare services company. It sources and distributes branded, generic, and specialty medicines to pharmacies, hospitals, physician practices, and health systems, while offering manufacturers commercialization, market-access, logistics, and clinical-trial support. Its economics are driven by the volume and mix of medicines moving through its distribution network and fees for specialized services.
Cencora Inc. (COR) has a MarketKingdoms composite score of 64.3 (B), an B-range rating. It ranks 895th of 1,866 covered companies, 40th of 78 in Healthcare (sector average 64.5) and 4th of 4 in Medical Distribution. Scores as of 2026-10-25.
Its strongest lenses are KPI momentum at 93 (Healthcare average 78) and Industry opportunity at 91 (Healthcare average 81). Its weakest lenses are Trend (momentum) at 31 (sector average 50) and Quality (profitability) at 34 (sector average 50).
| Lens | Type | COR | Healthcare average | Medical Distribution average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 91 | 81 | 91 | 100th |
| Stock selection | Research signal | 82 | 79 | 82 | 69th |
| KPI momentum | Research signal | 93 | 78 | 92 | 94th |
| Catalyst watch | Research signal | 73 | 74 | 76 | 41st |
| Price (valuation) | Fundamental lens | 71 | 50 | 68 | 83rd |
| Expansion (growth) | Fundamental lens | 50 | 50 | 54 | 56th |
| Quality (profitability) | Fundamental lens | 34 | 50 | 36 | 24th |
| Trend (momentum) | Fundamental lens | 31 | 50 | 51 | 26th |
The most recent call analysed was held on 2026-08-05 (fiscal 2026 Q3). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -7.0%: its price is below the path its market, sector and industry moves explain (undervalued versus the model path). Factor sensitivity: market beta 0.73, sector beta 0.01, industry beta 1.05; the factor model explains 59% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Cardinal Health Inc. (CAH) | 71.3 | B+ | -4.6% |
| McKesson Corporation (MCK) | 70.0 | B+ | +12.2% |
| Henry Schein Inc. (HSIC) | 67.6 | B | -16.7% |
Cencora Inc. financial statements · Healthcare sector ranking · Medical Distribution industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.